

Personal Information



SEE Hui Ti

Address: Parkway Cancer Centre

Country: Singapore

Curriculum Vitae

Medical Register

1. June 2008: Fellow of the Royal College of Physicians, United Kingdom
2. August 2004: Fellow of the Singapore Academy of Medicine (FAMS) (Medical Oncology)
3. December 2002: Specialist Register, Singapore Medical Council
4. October 1999: Clinical Teacher, National University of Singapore
5. February 1999: Member of the Royal College of Physicians, United Kingdom
6. March 1997: Singapore Medical Council
7. August 1996: General Medical Council of United Kingdom

Membership

1. Member of the American Society of Clinical Oncology. 2007-
2. Chapter of Medical Oncology, Academy of Medicine, Singapore: Member of the Chapter Specialty Board. 2005- 2007
3. Member of the International Gynaecologic Oncology Society (IGCS) 2003-
4. Member of the Singapore Society of Oncology (SSO) 2000-
EXCO Committee Member: Secretary 2003-2005
Treasurer 2001-2002
5. Member of the International Society of Pharmacoeconomics and Outcome Research (ISPOR) 2003-2005
6. Member of the Singapore Medical Association. 1997-

Previous Appointments

September 2005- June 2007

Visiting Consultant, Breast Unit, KKWCH, Singapore

May 2005-June 2007

Consultant, Department of Medical Oncology, National Cancer Centre, Singapore

January 2004- June 2007

Visiting Consultant

Gynaecologic Cancer Centre, KKWCH, Singapore

January 2003- December 2004

International Postdoctoral Fellow

Department of Gynaecologic Medical Oncology, MD Anderson Cancer Centre

Teaching Appointments

May 2001- April 2003

Clinical Tutor, National University of Singapore Medical School

May 2005- June 2007

Clinical teacher, Yong Loo Lin School of Medicine

Publications

1. Tangjitgamol S, See HT, Kavanagh J. Adjuvant chemotherapy for endometrial cancer. *Int J Gynecol Cancer*. 2011 Jul; 21(5): 885-95.
2. Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, Ilancheran A, Lee KM, Lim SE, Chia YN, Domingo E, Kim YT, Lai CH, Dali AZ, Supakapongkul W, Wilailak S, Tay EH, Kavanagh J; Asian Oncology Summit. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. *Lancet Oncol*. 2009 Nov;10(11):1119-27
3. Wong ZW, Ang PC, Chowbay B, Wong NS, See HT, Khoo KS. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer. *Breast*. 2008; 17(5):517-22.
4. Wong L, See HT, Khoo-Tan HS, Low JS, Fook- Chong S., Low JJ, Tay SK. Carcinosarcoma of the uterus: A comparison of the adjuvant therapy and outcome. *Asia Pacific Journal of Oncology*; 2006; 2(1): 57-63.
5. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. *Int J Gynecol Cancer*. 2006; 16(3): 1364-1369.
6. See HT, Thomas DA, Bueso-Ramos C, Kavanagh J. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. *Int J Gynecol Cancer*. 2006;16 Suppl 1:236-40.
7. Chen HM, Tan WH, Tan WC, Yu CK, Lim TH, Tay MH, See HT. Attitudes towards cancer survivors: a small survey. *Singapore Med J*. 2006; 47(2): 143-6.
8. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. *Int J Gynecol Cancer*. 2005; 15(4): 646-56.
9. See HT, Yong F, Cheung YB, Khoo KS, Ang P. Acceptance of prophylactic surgery and chemoprevention in an Asian country. *Annals of Academy of Medicine*. 2005; 34(3):238-42.
10. See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Kavanagh JJ. Retrospective review: retreatment of patients with ovarian cancer with carboplatin after platinum resistance. *Int J Gynecol Cancer*. 2005; 15: 209 216.
11. See HT, Kavanagh JJ. Novel Chemotherapy in ovarian cancer. *Cancer Investigation*, 2004; 22 (S2): 27-42.
12. Tangjitgamol S, See HT, Manusirivithaya S, Levenback CF, Gershenson DM, Kavanagh JJ. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. *Int J Gynecol Cancer*, 2004; 14(5): 804-14.
13. See HT, Kavanagh JJ, Hu W, Bast RC Jr. Targeted therapy for epithelial ovarian cancer. *Int J Gynecol Cancer*, 2003; 13(6): 701-734.
14. Cheung YB, Khoo KS, Wong ZW, See HT, Toh HC, Epstein RJ, Ng GY, Tan SB. Quick-FLIC--a short questionnaire for assessing quality of life of cancer patients. *Acta Oncol*. 2003; 42(1): 36-42.
15. See HT, Koo WH, Ang P, Au E, Ang PT. Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore. *Ann Acad Med Singapore*, 2002; 31(5): 651-5.
16. See HT, Hsu A. A breathless lady with lumpy kidneys. *Singapore Med J*. 1999 Jul; 40(7): 477-9.

Textbook Chapters/ Handbooks

1. See HT, Gershenson DM, Kavanagh JJ. Ovarian Cancer. MDACC Board Review Manual.
2. See HT, Kavanagh JJ. Gestational Trophoblastic Disease. MDACC Board Review Manual.
3. See HT, Freedman RS, Kudelka AP, Kavanagh JJ. Gestational Trophoblastic Disease. MDACC publication.
4. Tirado-Gomez M, See HT, Kavanagh JJ. Ovarian Cancer. MDACC publication.
5. Tangjitgamol S, See HT, Kavanagh JJ, Burke TM. Endometrial Cancer. MDACC Board Review Manual.
6. See HT, Rajan SK. Cancer of Unknown Primary. In A CLINICAL APPROACH TO MEDICINE edited by Ong Yong Yau, Woo Keng Thye, Ng Han Seong, Patrick Tan & Tang Ong Teng (Singapore General Hospital)
7. See HT, Chew L. Editors for the National Cancer Centre Medical Oncology Handbook for Junior House staff. Second Edition 2002
8. See HT, Chew L. Editor for the National Cancer Centre Medical Oncology Handbook for Junior House staff. First Edition 2000

Contributions in Chapters

1. Ovarian Cancer. In staging classifications and clinical practice guidelines of gynecologic cancers. FIGO Committee on Gynecologic Oncology, 2003.
2. Fallopian Tube Cancer. In staging classifications and clinical practice guidelines of gynecologic cancers. FIGO Committee on Gynecologic Oncology, 2003.

Meeting Abstracts

1. Ang P, See HT, Wong NS, Wong ZW, Wong CY, Chua ET, Tan PH, Ho GH. Ethnic differences in patients presented at a more locally advanced stage of breast cancer in Singapore- a single institution experience. Presented at 9th International Conference Primary Therapy of Early Breast Cancer, Jan 26-29, 2005. St Gallen, Switzerland. Abstract 120.
2. See HT, Walker PW, Palmer JL, Basen-Engquist K, Elsayem A, DeGracia L, Sun CC, Bodurka DC, Kavanagh JJ. Palliative Care Index for Ovarian Cancer. Presented at the 10th Biennial International Gynaecologic Cancer Society Meeting, Edinburgh, Scotland, October 3-7, 2004. Abstract 544.
3. Tangjitgamol S, See HT, Levenback C, Gershenson D, Kavanagh JJ. Third-line chemotherapy in platinum and paclitaxel resistant ovarian, fallopian tube and primary peritoneal carcinoma patients. Presented at the 10th Biennial International Gynaecologic Cancer Society Meeting, Edinburgh, Scotland, October 3-7, 2004; Abstract 719.
4. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/Neu, epidermal growth factor receptor, vascular endothelial receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Presented at the 10th Biennial International Gynaecologic Cancer Society Meeting, Edinburgh, Scotland, October 3-7, 2004; Abstract 222.
5. Toh CK, Leong SS, Lim WT, See HT, Fong KW, Lee KM, Wee J, Cheung YB, Tan EH. Do smokers and non-smokers with non-small cell lung cancer have biologically different disease? Presented in the proceedings of the 10th World Lung Cancer Conference; 2003 Aug 10-14. Vancouver, Canada.
6. Toh CK, Leong SS, Lim WT, See HT, Fong KW, Lee KM, Wee J, Tan EH. Characteristics of lung cancer patients referred to the Department of Medical Oncology, National Cancer Centre, Singapore. Presented in the proceedings of the 10th World Lung Cancer Conference; 2003 Aug 10-14. Vancouver, Canada.
7. Wong ZW, Khoo KS, Shah VA, Silverman C, See HT, Wong NS, Foo KF, Lim ST, Tay MH, Lim D, Toh CK. Phase I / II study of pegylated liposomal doxorubicin (PLD) and gemcitabine (G) as first-line therapy for metastatic breast cancer (MBC). Proceedings of the American Society of Oncology. 2002; 21: Abstract 2008.

8. See HT, Khoo KS. Gemcitabine–Vinorelbine Combination in Advanced Breast Cancer- NCC experience. Presented in Hong Kong, Orient-Europharma Regional Meeting March 2002.
9. See HT, Koo WH, Ang PT. Short Paper Presentation: Ten-Year Review of Tonsillar Lymphoma in Singapore General Hospital. Presented in Singapore- Malaysian Congress of Medicine August 1998